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Since the earliest days of cystic ﬁbrosis (CF) treatment, patient data have been recorded and reviewed in order to identify the factors that lead to
more favourable outcomes. Large data repositories, such as the US Cystic Fibrosis Registry, which was established in the 1960s, enabled
successful treatments and patient outcomes to be recognized and improvement programmes to be implemented in specialist CF centres. Over the
past decades, the greater volumes of data becoming available through Centre databases and patient registries led to the possibility of making
comparisons between different therapies, approaches to care and indeed data recording. The quality of care for individuals with CF has become a
focus at several levels: patient, centre, regional, national and international. This paper reviews the quality management and improvement issues at
each of these levels with particular reference to indicators of health, the role of CF Centres, regional networks, national health policy, and
international data registration and comparisons.
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Since the earliest days of cystic fibrosis (CF) treatment,
detailed summaries of large clinical groups have been
employed to determine and describe the best approach to
treatment, based on improved outcomes [1,2]. A comprehen-
sive approach to therapy, routine monitoring, and attention to
individual profiles and prognostic subgroups were highlight-
ed in these early papers on CF management. The early years
also included a cautionary tale, when mist tent therapy was
cited as the key component responsible for remarkable
survival in one large clinic, as documented in the newly
established US CF Registry [3,4]. Over the following decade,
however, it became clear that the scientific evidence of a
beneficial effect was lacking for mist tent therapy [5].
Nevertheless, the improved outcomes were real, and emphasis
was eventually, and more appropriately, placed on the
comprehensive management package, including early diag-
nosis, patient and parent education, frequency of patient
visits, daily physical therapy and aggressive antibiotic
therapy. It was also during this period that a new focus ongrowth and nutrition was evolving. Again, it began with
reports from a large clinic where greatly improved outcomes
were observed in patients with CF who were prescribed
a high-fat diet in place of the historical low-fat diet [6,7].
But it was only when the CF registry data for two
large, university-based clinics with similar demographics
and approaches to other aspects of treatment were compared
that the possibility of a normal diet and the goal of normal
growth in patients with CF were widely embraced [8].
Although the benefits of specific treatments must be
supported by evidence from well-controlled studies, there is
great value in compiling and comparing outcomes in large
clinical populations in order to document changes over time
and to identify patterns and practices that may be associated
with benefit or concern. Of particular importance are national
registries that account for all, or a large and well-defined
proportion of, CF patients in a region. National, annually
updated CF registries in the USA since 1966 [9] and Canada
since 1970 [10] were instituted primarily to describe
population patterns of diagnosis, demographics and mortality.
Over the years additional information was added to track
Fig. 1. Levels of quality management in CF. P, patient; C, cystic fibrosis Centre;
R, regional governance, quality groups; N, national healthcare policy, registries,
benchmarking; I, international guidelines and recommendations. The Dart-
mouth approach illustrates the different levels in clinical care: the microsystem
level (patient, family cystic fibrosis care team); the mesosystem level (hospital);
and the macrosystem (healthcare organizations, networks, governance) [27].
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and growth. Near the turn of the century, the US CF registry
began to compute centre-specific summaries, which allowed
CF Centres to locate themselves in the range from low to high
performance for several key measures. The CF Foundation
(CFF) Quality Initiative [11] was launched to support Centres
in a concerted effort to improve poor outcomes and emulate
the successful strategies of Centres with consistently good
outcome measures. Several European countries have
established CF registries, as have Australia and New Zealand,
and there is an ongoing effort to orchestrate a European CF
registry combining existing national registries with data from
countries without a registry [12]. The European Cystic
Fibrosis Society Patient Registry [13] was founded in 2004
and was based on the entry of defined demographic and
clinical data. Later demographic data from CF registries
collected during the European 6th framework Coordination
Action project (2006–2010) provided evidence on disparities
in care between Western and Eastern European countries. By
the beginning of 2013, 20 European countries participated,
representing more than 18,000 patients with CF. Annual
reports are available [14], and the first comprehensive
analysis has been carried out [15].
Several quality management programmes have evolved,
with Centre comparison as a primary motivation. Early
registry development in Germany was called the Cystic
Fibrosis Quality Assurance (CFQA) project [16], and
occurred long before the idea of publishing Centre-specific
summaries was deemed acceptable in other regions. Whereas
most registries report survival into the middle adult years, a
report from South America [17] is a sobering reminder that
attention to the quality and delivery of care is of primary
importance.
As well as large Centre databases and national registries,
there have been initiatives from the pharmaceutical industry
to collect longitudinal data following large multicentre drug
trials, to provide Phase IV analysis of treatment effects, and to
study other prognostic factors. The Epidemiologic Study of
Cystic Fibrosis (ESCF) [18] was a multicentre observational
study that funded the collection of large amounts of clinical
data on patients in participating Centres in the USA and
Canada. The representativeness and continuity of the ESCF
were complicated by funding issues, so that age and regional
distributions and patterns over time were not always easy to
interpret. But their analyses certainly intensified the interest in
comparative studies and addressed many questions that will
be more appropriately addressed by analysis of national
registries, as more and more of them become poised to
participate.
Issues of patient confidentiality and authorship in any
publication must be addressed at an early stage of the planning
of such studies. The equivalence of standard measures across
populations, and even within populations, cannot be assumed
and is another challenge in comparisons using registry data.
The history and issues of benchmarking quality of CF care
using registry data have been summarized in a recent review
paper by Schechter [19].The ongoing Early Pseudomonas Infection Control
(EPIC) study is an example of an observational study,
supported in part and ‘at arm's length’ by the pharmaceutical
industry, that combines registry follow-up with a study-
targeted young American CF population. The study aims to
answer specific questions about the early stages of the CF
disease process and treatment options [20]. An Australian
study of patients with CF identified at newborn screening
highlights the difficulty of defining metrics for assessing
progress, and by extension quality management, in the
youngest patients [21]. Follow-up of well-defined groups of
young patients with CF, especially those diagnosed by
newborn screening, gives the best chance of describing and
refining the best treatment practices [22].
Effective quality management at all levels must recognize
the contributions and the needs of all partners in the process,
from the medical experts and care personnel, to the patient
and family members, and the analysts and interpreters of
results. The processes for provision of data and access to data
must be transparent and audited regularly. There must be a
balance between the process and proposed outcomes so that
all Centres can participate at a level compatible with their
size, funding and stage of development. Analysis of changes
over time and region, with appropriate recognition of known
and potential confounders, will provide knowledge and
guidance for the continuing improvement of care and out-
comes in CF.
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improvement. Quality improvement in healthcare has been
defined as ‘an interdisciplinary process to raise the likelihood
of the delivery of best practices for preventive, diagnostic,
therapeutic, and rehabilitative care to maintain, restore, or
improve health outcomes of individuals and populations’
[23]. Quality improvement is a science [24] and includes
numerous distinct strategies for changing patient and provider
behaviour, as well as redesigning systems of audit and
feedback, case management, support for self-management,
patient registries and computerized decision support [25].
But, the single, most basic approach involves iterative cycles
of outcome measurement, identification of problems, imple-
mentation of potential solutions and repeated measurement
[26].
Quality management in CF takes place at different levels:
patient, Centre, regional, national and international (Fig. 1).
The Dartmouth approach of systems embedded in systems
acknowledges different levels of clinical care: the micro-
system level involves the patient, their family and the
specialist CF care team; the mesosystem level is the hospital/
CF Centre in which the care is provided; and the macrosystem
level includes healthcare organizations, networks and gover-
nance [27]. This paper reviews quality management issues at
each of these levels.
2. Quality management at the patient level
2.1. Use of registry data
Patients are at the centre of all efforts to improve quality
of care. This implies that they take an active part with CF
teams in the continuous process of quality improvement. The
use of CF registry data in daily care has been shown to be
helpful in this respect [28–31]. Classical outcome indicators
describing nutritional status and lung function are shared
with patients at the site of the visit [32] and are expected
to help promote different strategies to improve quality of
care, with positive consequences on quality of life and life
expectancy.
2.2. Patient-centred approach
Patients are the subject of care, but also experts on life
with CF and their expertise can complement that of the CF
healthcare professionals. The patients and their family are
involved in quality improvement at all levels and their
collaboration is a fundamental prerequisite. Full respect, trust
and transparency should exist between partners, with co-
responsibility for success and compliance with treatment.
There should be an openness and willingness to learn from
each other.
Different steps are included in this quality improvement
process. Electronic files based on appropriate software (e.g.
Port-CF, MUKO.dok., ECFS Registry) are a necessary
precondition. Appropriate data and follow-up parameters
may be grouped or individually presented to show changesbefore and after therapeutic measures have been taken. These
electronic files and follow-up charts may inform periodic CF
team sessions and regular quality improvement conferences,
centred on individual patients/parents.
International and national guidelines form the basis of
different steps of therapy. Annual therapy goals can be set
together with the patients/parents; therapy contracts may even
be negotiated.
In the respiratory and nutritional fields, positive experi-
ences highlight the successful implementation of quality
improvement steps in CF patients and patient groups. For
example, the natural progression in decline in forced
expiratory volume in 1 s (FEV1) [33,34] can be counteracted
by different therapeutic interventions, such as anti-infectious
and anti-inflammatory therapy and also by emerging new
treatments for subgroups of patients [35–37]. Adherence to
pulmonary guidelines [38], and education and training of
physicians, families and patients [39] are successful quality
improvement interventions that improve important outcomes.
Key objectives are prevention and early treatment of
exacerbations. For this, a patient checklist to be included in
the electronic files is helpful to increase patient awareness of
the early signs of exacerbation. Algorithms on what to do
when FEV1 declines are an additional useful instrument and
should also appear in the electronic files and be transparent to
patients.
A similar experience has also been reported for nutritional
interventions. Many patients do not follow nutritional
guidelines and recommendations [40,41]. This has a
negative impact on the disease because adequate nutritional
counselling, increased caloric intake and a good nutritional
status are linked to favourable outcomes. In single cases an
individually adapted strategy may be adequate. Quality
improvement efforts have included individual and standard-
ized nutrition plans and also behavioural and nutrition
interventions to improve nutritional status in patients with
CF [42,43].
Additional quality improvement projects, such as Centre
care networking, individual quality improvement projects,
group efforts and benchmarking are based on connecting
patient data, registry data and individual efforts. There is also
space for telehealth and patient-driven initiatives. Thus,
quality improvement at the patient level is a central and
decisive part of quality management in CF, accompanied by
further and wider approaches at other levels.
2.3. Public reporting
Appropriate CF care and continuous improvement of
clinical management are necessary to augment the well-being
and quality of life of patients with CF [44]. Patient registries
are of utmost importance not only from the experts' point of
view but also from the patients' perspective. As well as
providing reliable and comparable data in a given country,
they also represent a valuable tool to lobby appropriate CF
care. Registry data should be made available to patients and
national health authorities [45]. In many European countries,
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national health budget. It is important, however, that the data
are presented in a patient-friendly way [46], and that patient
representatives are trained in interpreting them.
In the USA, patient outcomes of each CF Centre have
been laid open since 2006 (www.cff.org//CCNP/CareCenter
Selector/Index.cfm). Interestingly, this effort did not lead
patients to move to better performing Centres in any
meaningful numbers.2.4. Quality of life assessment
Over the past 20 years, a number of instruments have been
developed to measure patient health status and to assess
how patients feel or function with regard to their health
conditions [47]. The questionnaires that measure quality of
life in patients with CF (the revised CF questionnaire
[CFQ-R] and the Cystic Fibrosis Quality of Life (CFQoL)
questionnaire) are considered valid instruments with demon-
strated reliability, internal validity, and sensitivity. As
pulmonary exacerbations are clearly associated with worse
symptoms of lung infection and health perception, these
questionnaires represent an important tool to be used with
clinical questions and national and international surveys,
among other endpoints (clinical efficacy measures, surrogate
endpoints or biomarkers) [48]. The European Medicines
Agency recommends that in addition to demonstration of
efficacy of treatment, a demonstration of benefit on
health-related quality of life should be performed in CF trials
[49].2.5. Patient satisfaction assessment
‘Patients feel confident when looked after by medical
personnel who are experienced in the care of their
condition’ [50]. Therefore, quality improvement measures
that start from patient satisfaction are under development in
several countries. In Germany a nationwide study was
conducted that examined patients' experiences and satis-
faction with the care provided at their Centres [51]. The
response rate of 71–74% is a reflection of how interested
patients are in contributing to improvements in the quality
of their care.
However, quality improvement measures focusing on
patient satisfaction are only useful if the results are discussed
between CF teams and patient representatives. A way to
organize such an ongoing and continuous reflection is
to establish discussion groups that meet regularly. Such
discussion groups may also offer a straightforward tool to
improve care management in those countries where quality
assessment and improvement measures on a national level
are just about to start. Discussion groups do require a lot of
good will on the part of the caregivers, as well as training of
the patient representatives involved.A summary of the elements of patient-centred quality
management is shown in Table 1.
Questions and AnswersQ1 What is the contribution of electronic patient files
and follow-up charts in quality management in
CF care?
A1 Electronic patient files and follow-up charts are a
basis for sharing data with patients, for individual
comparison, Centre charts and for definition of
therapy goals.
Q2 How can appropriate respiratory and nutritional
measures be installed and controlled individually
in CF care?
A2 By following national and international standards
and definitions and using defined normal values in
different age cohorts, best practice can be marked
and individual aims can be set and managed.
Q3 What is the contribution of patient-reported quality
of life data and patient satisfaction questionnaires
in quality improvement work?
A3 Patient-reported quality of life data are an impor-
tant subjective adjunct to description of quality at
satisfaction and compliance level. Patient satisfac-
tion questionnaires are opening up an additional
dimension of interaction between patient and CF
Centre in quality improvement.3. Quality management at the Centre level
3.1. Centre care, certification and peer review
CF Centre care and the use of national and international
patient registries have become essential features of health-
care and information exchange in the field of CF in many
countries. Since 1995, the German CFQA project has
collected demographic data and outcome parameters and
the registry has evolved from a standard registry into an
instrument of quality management. The German CFQA
project also serves as the backbone in supporting quality
assurance groups and as a benchmark project [30]. Quality
management is now a major tool in CF Centres and is
maintained by national registries. The analysis of registry data
could lead to the certification of CF Centres as well as to the
guided planning of structures and strategies in CF care.
It could also serve as a basis for political action in the
healthcare system and for improvements in quality awareness
at all levels (individual, Centres, quality groups, political,
charity institutions) [52].
The CF Trust peer-review programme assesses services
against national standards of care, identifies shortfalls and
helps CF services to improve the care they provide. A
Table 1
Patient-centred quality management.
Practical points and tools
• Electronic patient documentation
• Patient follow-up charts
• CF team sessions, discussion of single patients
• Setting quality goals
• Patient and Centre checklists
• Adherence to guidelines
• Planned intervention
• Education and training of physicians, families and patients
CF, cystic fibrosis.
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reports being made available to the public for the first time,
providing comprehensive, independently verified infor-
mation about the performance of individual CF services
[53].
It is now recommended that CF patients should be cared
for by a multidisciplinary team of specialist doctors, nurses
and allied health professionals at a recognized specialist CF
Centre.
3.2. Models of care, consensus documents
Different models of care have been outlined. The definition
of the CF Centre, number of patients treated at the Centre
(both lower and upper limit) as well as the number and
expertise of staff members are given by different national and
international consensus documents, including the Centre
Framework paper in this supplement [50,54,55].
Questions and AnswersQ1 Do we have a nationwide definition of the
specialist CF Centre? Can we agree on patient
numbers and required staffing levels at CF
Centres?
A1 The level of expertise required to treat the
complex multisystem symptoms and com-
plications of CF can only be acquired by a
multidisciplinary team of trained, experienced,
specialist health professionals who routinely see
a critical mass of patients at a specialist CF
Centre.
Q2 Do we have an agreement about key markers
for evaluation of performance of specialist
Centres?
A2 The following are examples of key markers used
in many countries:
i microbiology, rate of new and chronic infec-
tions, lung function data, age groups
ii nutritional data (body mass index percentile,
body mass index, age groups).
[For more details see Section 6].
Q3 How can data collection and public reporting of
care Centre data be a part of the quality
improvement initiative?
A3 By sharing data, the partnership between
patients and caregivers can be strengthened.
The analysis of data and establishment of
national peer-review programmes could be
used for the certification of individual CF
Centres. It could also serve as a basis for
political action in the healthcare system and for
improvements in quality awareness at all levels.4. Quality management at the regional and national level
The fundamental requirements for a functional and effective
healthcare system is for all parties – patients, families, payers,
healthcare professionals, healthcare system leaders and
communities – to produce better outcomes for patients, better
professional development and better performance for the
healthcare organizations [56]. Quality and safety are the
consequence of the functional interaction between healthcare
providers and patients at the microsystem level, but physical
resources, adequacy of funding and health policies influence
both.
4.1. Health policies
Public health policies at the macrosystem level (either
national or regional levels, depending on the country) include:
1) quality accreditation of care organizations, based on
professional practice evaluation; 2) risk management, for
instance to decrease iatrogenic disease and improve hygiene
precautions; 3) professional development through continuous
training and rewards.
Private policies, such as those developed by pharmaceutical
companies or patient and family foundation initiatives, may
complement or interfere with national public health policies.
National or regional health policies and private initiatives need
to converge into consistent incentives to sustain the engage-
ment of professionals in continuous quality improvement over
time. An example of this is the link between newborn screening
and subsequent Centre care of the newly identified patients
based on consensus [57].
From the European public health policy perspective CF is
classified as “rare disease” (i.e. occurring with the prevalence
lower than 5 in 10,000 individuals) according to the
“Regulation (EC) No 141/2000 of the European Parliament
and of the Council from of 16 December 1999 on orphan
medicinal products”. In this regard CF Centres should be in
compliance with the European Union Committee of Rare
Disease Experts guidelines for “Centres of Expertise for rare
diseases” so that these could cooperate within the frame of
European Reference Networks for Rare Diseases. This
macrosystem measure is important since rare diseases (hence
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European “Directive 2011/24/EU of the European Parliament
and of the Council of 9 March 2011 on the application of
patients' rights in cross-border healthcare”. Such special
status is potentially very important for CF centres located
within the European Union in terms of reimbursement of CF
care for patients originating from another Member State,
including provision of transnational sharing of expertise,
exchange of staff and eventually also of CF patients in
selected instances (e.g. in those cases who could benefit from
highly specialized care in a better resourced centre, or when
local conditions would be temporarily unfavourable, or for
patients from less favoured regions of the European Union).
Finally, the rare diseases status also facilitates development
and registration of orphan medicinal products (e.g. CFTR
modulating therapies) by the industry and the European
Medicines Agency, respectively.
4.2. Strategies of quality management at the national level
As the EuroCareCF analysis of demographic data from 35
countries shows, there is no single approach or strategy that
works in all situations. However, there are principles that
can help to develop a strategy suited to the situation in a
particular region [58]. A strategy is a process, a way of
agreeing what is to be done and by whom, and of ensuring
that quality work is carried forward [59]. Strategies and
experiences in several European countries are listed in
Table 2.
4.3. Quality improvement learning collaboratives and learning
and leadership collectives
Learning and leadership collectives (LLC) involve several
care Centres in a yearly quality improvement programme.
The programmes are based on the Dartmouth Institute
Clinical Microsystem Approach (an action guide for accel-
erating the rate of quality improvement in CF care), and
involve the training and coaching of the multidisciplinary
care teams through four phasesTable 2
European quality management strategies and experiences.
Country Quality management strategies Principles — initiatives
France LLC and best practice Continuous professional
development
Germany Benchmarking and best
practice, Centre
certification
Quality of patient
outcomes
Italy Peer reviews and
accreditation
Patient and family
involvement as peers
UK Peer reviews and LLC
(site visits)
Quality of patient outcomes and
processes (adherence to guidelines)
LLC, learning and leadership collaborative.• preparation phase
• 5P analysis (i.e. product, price, programme, process, people)
and assessment of the Centre
• action phase, and
• transition phase.
Health systems in the USA, Germany, Sweden, the UK and
France pursue quality improvement through learning strate-
gies. Clinical outcomes attributed to quality improvement
learning collaborative (QILC) include: identification and
adoption of systematically studied evidence-based practices,
decreased neonatal infection rates, cost-conscious prescriptive
practices, improved patient safety, decreased emergency
department waiting times and improved management of
persons with chronic illness [19,29,60].
Key factors associated with successful collaboration for
quality improvement include availability of resources to
support changes, multidisciplinary involvement, agreed aims
and agenda, project ownership among members, and the
essential role of leadership. These conditions depend on
personal contact between participants, wide networking,
mutual respect among all parties, accessibility of data and
information sharing. Diversity among members strengthens
the collaborative by contributing a range of perspectives [61].
The CFF (USA) has developed LLCs [2]. The Dartmouth
Institute Clinical Microsystems approach was used as the
framework to improve the quality of CF care in the USA.
Modelling on the US-CFF quality improvement initiative, a
pilot QILC was initiated in France in 2011 and demonstrated
that the US approach including national coordination and
coaching is appropriate [62] with a few adjustments, namely the
need for a part-time member of staff in each Centre whose role
is one of a local coach, working closely with the physician
leader of the CF Team.
An external evaluation highlighted the existence of
obstacles, such as limited time and resources, staff and
organizational changes, and lack of accurate and up-to-date
information to measure outcomes [19,62]. These shortcom-
ings were positively balanced by success factors, mainly
motivation of the CF team, a culture of patient-centred care,
patient and parent involvement, physician leadership and clear
agreed goals.
4.4. Ranking and learning from best practice (benchmarking)
Benchmarking involves the identification of healthcare
programmes associated with the most favourable outcomes
as a means to identify and spread effective strategies for
care delivery [56,60]. Variation in processes and outcomes
suggests differences in the efficiency of delivery of care,
and offers the opportunity to gain knowledge of the level
of success that may be obtained with currently available
therapies.
Quality benchmarks in CF use key nutritional and
respiratory assessments such as body mass index (BMI),
FEV1%, bacterial status and complications. Patient registries
include annual data derived from the data collected at each
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registries exist with high-quality data, ranking of the Centres
offers the opportunity to identify potential best practice for
treating patients with CF.
The next step is to attempt to determine how their
excellence was achieved [19,31]. The US CFF supported a
benchmarking programme that used registry data to identify
clinically excellent CF Centres and then to study their
structural and cultural organizational features in addition to
the specific practices that contribute to their outcomes. The
underlying principle is that the practices and/or characteristics
identified at high-performing Centres are drivers (and not just
markers) of outcomes, which can be translated and applied to
other Centres that are not performing so well.
A number of pitfalls complicate attempts to ascertain best
practice [19]. Attention has to be paid to biases between
Centres due to case mix. For example, Centres following
patients with proportionately milder mutations may have
better indicators than Centres following more severe patients
(e.g. those registered on a transplantation list). Centres with
small numbers of patients may present great variation in their
indicators depending on the health status of just a few patients.
Adult care Centres are fed by paediatric programmes, which
determine the baseline disease status as well as the education
of patients. Socioeconomic factors affect the population
of patients in some Centres according to their location. It
is important to consider case-mix adjustment to control for
disproportionate distributions of sociodemographic and
disease-specific risk factors at some programmes and loca-
tions, even if this may introduce new bias into the comparison.
Beyond the registry data, several key themes emerged from
the benchmarking work: 1) the presence of a well-functioning
care team working with a well-thought-out systematic
approach to providing consistent care; 2) high expectations
for outcomes among providers and families; 3) early and
aggressive management, avoiding reliance on rescue thera-
pies; 4) patients/families who are engaged, empowered and
well informed on disease management and its rationale [63].
The most frequently used criteria for benchmarking and peer
review are as follows:
• physician leadership
• multidisciplinary care team
• access to care
• infection control
• sweat test quality
• follow-up care guidelines
• patient and family satisfaction survey.
4.5. Guidelines
CF care at the national/regional level has to adapt
international guidelines (USA and Europe) to the local
context. Adaptation means translation into the local language,
adaptation to the context of the organization of care,
dissemination through the Centres, and assessment of their
implementation in the CF Centres. A successful experience[39] of appropriating international guidelines is illustrated by
Cincinnati Children's Hospital, which set up a framework for
adherence to prescribing guidelines in an outpatient setting,
educating clinicians and sharing goals with families.
4.6. Peer review and quality accreditation programmes
Peer-review programmes enlist professionals to monitor the
quality of patient care provided by their colleagues, in order to
identify opportunities to improve the quality of patient care.
They are designed to monitor the quality of the healthcare
services offered to patients, to identify opportunities to improve
patient outcomes, and to identify and prevent malpractice [64].
In the EU there are different quality improvement
accreditation programmes involving the peer-review method.
The activity of preparing and undergoing accreditation has
been shown to promote change in health organizations. It is
important to:
• assure a minimum standard of care in every Centre; the
standard must be set at the maximum achievable level, in the
national/regional context, in order to stimulate improvement
over the time;
• foster exemplary care, encouraging and supporting care
Centre development;
• support new Centres in starting their activity;
• improve clinical outcomes.
At the national/regional level, a key recommendation is that
a multidisciplinary committee, including patient and family
representatives, should be established in order to start and
develop programmes of peer-review accreditation according
to published European standards. These programmes should
be adapted to local needs and resources, to stimulate CF
Centre improvement over time. Table 2 shows examples of
national peer-review programmes.
4.7. Information systems at the national/regional level
According to the World Health Organization [65], informa-
tion systems need to apply consistently across the whole quality
improvement programme so that comparisons in outcomes and
progress can be made between parts of the programme. These
information systems also need to be transparent, so that the
widest possible range of stakeholders has access to the same
information. The scope of the information includes: the
availability to healthcare workers of information about best
practice; the way in which the information is given to service
users by those providing care; and the access by communities
and individuals to information that will help them manage their
own health. Any of these areas might require change as part of a
strategy for quality improvement [65].
4.8. Measurements
In the course of a yearly collaborative quality improvement
programme, key indicators and their current value are shared
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harmonization and quality control of the data in the Centres.
Results must be interpreted carefully and scientific measures
should be applied to identify trends and factors of variability
for the accurate monitoring of quality improvement work [66].
The attention paid to the measures during Plan–Do–Study–
Act (PDSA) cycles and to the underlying causes of variations in
measures between Centres [60,66] is key to continued quality
improvement.
4.8.1. PDSA cycles
Quality management is carried out using PDSA cycles,
leading from a quality improvement plan (plan), to measuring
appropriately and surveying quality indicators to changes in
practice (do), to finding out about best practice (study), and
finally, to induce new quality-improvement steps that will meet
standards and guidelines and approach quality goals (act).
The results of quality improvement initiatives are not
reported in the same way as traditional clinical research.
Quality improvement reports tend to address ‘messier’
problems, involve more complex interventions, and require
far greater attention to context. The ‘messiness’ of problems in
quality improvement is a reflection of the real-life setting and
the focus on routine care rather the controlled environment of
a clinical trial. For example, an improvement project might
ask: can patient outcomes be improved by changing the
referral and appointment system to ensure timely access and
better coordination between specialist and primary care
services? [67].
To drive improvement efforts, an annual report of patient
outcomes, based on one value derived from the different
measurements of the year and issued several months after the
end of the period is not appropriate. Actual data that are
updated at each visit and displayed on graphs incorporating
the evolution in processes, delivery of care and patient
outcomes are essential to provide feedback on the implemen-
tation of treatment/service improvements plans. This requires
a CF information system to collect patient data regularly andTable 3
Tools and methods to achieve quality improvement [56].
• Delineate healthcare process
• Collect data over time to document variation in care practices and clinical
outcomes
• Document unwanted and unnecessary variation
• Collect information regarding customer/beneficiary knowledge (e.g. measure-
ments of illness burden, functional status, quality of life; recipients' assessment of
the quality of their care)
• Adopt widespread public sharing of information
• Improve communication by building teams and enhancing group learning
using specific skills (e.g. situation, background, assessment and request
[SBAR])
• Create a leadership plan acknowledging: leading, following and making
changes in healthcare
• Build knowledge (locally useful) then take initiative and use adaptive action,
reviewing and reflecting
• Make small tests of change (e.g. Plan–Do–Study–Act cycles)to track the care delivered at each visit, and database
management that issues reports for the team on weekly,
monthly and quarterly bases.
Standardization, completion and quality control of the data
collected at the Centres are essential to the relevance of the
measure. Part of the improvement shown by the indicator
comes from a higher quality of data collected. BMI or FEV1%
are significantly dependent on the conditions of measurement
(e.g. before or after a meal, related to the scale used, before or
after physiotherapy).
Over the past 20 years, the concept of improvement of
healthcare systems has moved away from top-down control,
compliance and punishment towards bottom-up development,
self-regulation and incentives. Quality measurement has
shifted from resource inputs to performance outputs. Empha-
sis has moved from quality control and assessment to the
definition of agreed and valid standards, systematic and
reliable measurement of performance, implementation of
action for change, repeated measurement and continuous
improvement in a cycle or upward-moving spiral [68]. Thus,
the new quality improvement tools of benchmarking, learning
from best practice, PDSA cycles, LLC and accreditation are
more adequate to accomplish quality improvement in CF.
These methods are summarized in Table 3.
5. Quality management at the national level
5.1. Quality improvement
Not uncommonly, practitioners in a specific clinical setting
will fail to prescribe recommended treatments; the reasons
for under-utilization of recommended efficacious therapies
are often site specific and relate to structural or educational
barriers. Through an iterative process of quality improvement,
one can begin to identify and intervene on the barriers to effect
change in care.
5.2. Registries in quality improvement
In order to begin work in quality improvement, one needs
to have a measure of the scope of the clinical problem. One
of the key components of quality improvement is access to
high-quality data regarding patient characteristics, treatments
and clinical outcomes. Such data sources have historically
been patient registries. Registries permit investigators and
stakeholders to document variation in care where variation
would not be anticipated. CF is ideally suited for evaluation of
quality improvement research because of the existence in
many countries of comprehensive patient registries. Some of
the very early patient registries in CF were set up [9,10] to
establish a more unified understanding of CF and to measure
quality improvement. In 1966, the CFF Patient Registry
(CFFPR) was started for this purpose and now contains
detailed data on more than 26,000 individuals with CF [9].
The CFFPR has been used to evaluate survival and temporal
changes in survival [69], predictors of survival [70], impact of
sputum microbiology [71] and complications related to CF
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the UK CF Registry) identifying use of gentamicin as a
particular risk factor for renal failure in CF [73] and
highlighting the relationship between diabetes control and
survival [74]. More recent publications from the USA have
addressed process of care and access to care, which are key
topics in quality improvement [29,75]. Johnson et al.
evaluated US CF Centres, ranking these Centres based on
the median FEV1 within each of three age groups
(6–12 years, 13–17 years and ≥18 years). They found that
those Centres that saw their patients more frequently, with
attendant lung function tests, sputum microbiology and more
antibiotic use, consistently ranked higher [75]. These
investigations can then lead to the design of interventions
that improve care practice and patient-centred high-value
outcomes.
5.3. Guidelines in CF for quality improvement purposes
One of the key elements of quality improvement is a clear
understanding of what constitutes appropriate and
high-quality care. One of the goals of quality improvement
is to ensure that recommended treatments are indeed offered
and utilized by patients in whom the treatments have de-
monstrated efficacy. Guideline documents have been pub-
lished to help the CF community evaluate the existing
evidence and establish standards of care (e.g. care of the
infant and treatment of lung infections) [57,76]. These
documents provide a systematic approach to evaluating the
literature and a set of recommendations that can then be
integrated into benchmarking. Such documents represent the
standards for current care in CF, creating a roadmap to
continued success in the management of this disease. One of
the key challenges of guidelines is that they can differ in their
recommendations. These differences may be due to differ-
ences in healthcare systems, interpretation of data, and
interpretation of risks and benefits of interventions. Guidelines
are clearly fluid and will change over time as more
information is gathered regarding approaches to CF care.
5.4. Nationwide benchmarking in CF for quality improvement
purposes
In many countries patient advocacy groups have set goals
to improve the survival and outcome of individuals with CF.
These groups represent the earliest phase of quality improve-
ment in CF. As a result of these efforts, quality of care
for people with CF has improved significantly, with an
associated improved survival [46]. Development of patient
registries has been the engine behind this success. Although
improving survival is a key goal in quality improvement and
benchmarking, other important metrics should also be
tracked. There have been several key advances in this area
over the past decade. German CF Centres have made quality
improvement a major focus in their CF care [16,30].
This project was able to demonstrate first the temporal
improvements in outcome and then improvements in care butimportantly, it demonstrated variation in care practices
among the 93 Centres in Germany. The project then
developed benchmarking indicators and a PDSA cycle [60].
As results from this work translate into change in care
practice, continued improvement in CF outcomes will be
realized [31]. In another example, in 2006 in a move toward
benchmarking, the US CFF made Centre-specific perfor-
mance indicators transparent to the public, promoting this
action as an initiative to ‘accelerate the rate of improvement’
through benchmarking. Top-performing Centres were used as
models of best practice with the hope of disseminating
successful processes to other Centres, and thus reducing
national variability in practice patterns and outcomes. The US
CFF also launched a series of action-oriented training
programmes (LLCs) to increase the capacity for quality
improvement across the CF clinical care network [77]. Each
Centre participating in one of the LLCs performed a quality
improvement project over the course of a year. Examples
included a project to standardize pulmonary exacerbation
care [78] and benchmarking to improve the screening rates
for CF-related diabetes [29].
5.5. Role of quality improvement in newborn screening
Newborn screening provides a unique opportunity for
quality improvement in CF. Identifying individuals at birth
provides several windows of opportunities to intervene early
in the disease. Such interventions could lead to the prevention
of structural lung disease occurring prior to clinical symp-
tomatology in CF babies [79]. Newborn screening allows CF
providers and researchers to more formally understand the
early events that lead to later clinical disease [35] and evaluate
the role of earlier interventions [80]. Recent work made
possible by newborn screening was employed to establish a
definition of exacerbation in very young children [21].
Understanding best practices, how to benchmark care, and
how best to track children with CF identified by newborn
screening will be essential to further advance the care of these
patients. Guidelines and standards of care are now available
for the management of this particular CF population and will
remain essential [57]. National data registries will need to
change accordingly to track clinical interventions and
outcomes. A key challenge remaining relates to the limited
data for treatments early in disease and the challenges to
establish treatments in this patient population. In addition
from a larger perspective, newborn screening poses new
challenges and opportunities to ensure early and timely access
to care for persons with CF and potentially access to new
promising therapies for eligible patients.
Challenges will also remain given the differences in
algorithms for newborn screening. All screening tests involve
trade-offs between sensitivity and specificity. Marked differ-
ences have been noted in positive predictive value depending
on the approach taken [81,82]. One of the key issues with
regard to choosing different protocols for newborn screening
will be the identification of carriers and understanding
the natural history of the rarer genotypes identified through
Table 4
Proposed indicators for healthcare services.
Area Proposed indicator
CF Centre
definition
Funding of CF Centre guaranteed by the
provider of medical care
Number of patients followed
Establishment of links with consultants with
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screening into patient registries will help to clarify some of
the key issues that arise from screening.
Questions and answers
expertise in the fields recommended in the
standards of care consensus
Presence of referral and assessment protocol
with a transplant Centre
Availability of a radiology department with
CT scanning facilities
Availability of a pulmonary function laboratory
Availability of a microbiology service with
established contacts with a CF microbiology
reference laboratory
Availability of diagnostic capability including
sweat testing and CFTR gene mutation analysis
Availability of guidelines for the treatment of
CF complications
24-hour access to the CF Centre for
telephone advice, emergencies or consultations
Members of
the team
Presence of CF Centre Director
Presence of CF Consultant
Presence of CF Clinical Nurse Specialist
Presence of CF Physiotherapist
Presence of CF Dietitian/Nutritionist,
Presence of CF Social Worker
Presence of CF Psychologist
Presence of CF Clinical Pharmacist
Presence of CF Clinical Microbiologist
Presence of consultant, registrar, staff grade
specialist nurse, physiotherapist, dietitian,
social worker, psychologist, secretary,
pharmacist for the full-time equivalent [90]
Outpatient
care
Frequency of visits
Place of visit
Presence of CF physician and nurse at every visit
Accessibility of all members of the team at every visit
Execution of recommended routine tests, as
appropriate for the age of the patient
Revision of treatment and medications
Implementation of segregation policy
according to patient microbial status
Admission or home intravenous treatments within 24–48 h
Inpatient care Number of beds to allow immediate admission
Presence of infection control policy
Availability of single rooms with en-suite
toilet and bathroom
Availability of hand-washing facilities
Availability of concomitant review by allied
health professionals
Assessment of hyperglycaemia and overnight
oxygen saturation at each admission for infective exacerbation
Regular sputum microbiology
Regular spirometry measurement
Physiotherapy (including sputum mobilization
techniques), twice dailyQ1 How does one ensure that high-quality accurate
data are recorded in registries?
A1 One could consider doing random on-site audits
in addition to electronic data audits.
Q2 Should patient registries go through routine
validation steps given the role they have in
measuring and assessing quality of care?
A2 Validation could include data audits but also
validation of data steps involved in generated
specific high-value outcome measures (e.g.
FEV1% predicted).
Q3 How can registries achieve standardized defini-
tions of data elements and standardized reporting
to ensure improved comparisons when performing
comparisons between countries?
A3 This could be achieved by creating an interna-
tional working group on registry standardization.
Q4 How can registries reduce the time from data entry
to feedback of results to Centres and patients?
A4 One solution could entail real-time data entry.
Q5 What are the essential data elements related to
newborn screening that need to be collected in
registries to establish appropriate quality mea-
sures in the future?
A5 Potential variables include age of screening,
approach taken for screening and results of
screening
Q6 How do countries address variable newborn
screening protocols within their borders?
A6 This could be addressed by having a clear outline
of all approaches to newborn screening and to
have a data element that clearly lists the approach
taken for each individual.
Q7 How should patient registries be employed to
formally evaluate newborn screening protocols?
A7 One strategy would be to compare the introduc-
tion of newborn screening with interrupted time
series analysis in nations, provinces or states with
differing times of introduction of these protocols.Availability of facilities for supervised physical exercise
Availability of protocols for dosing and
administration of antibiotics, treatment of a
pneumothorax, management ofhaemoptysis,
diagnosis and treatment of ABPA and CF-related diabetes
Weekly discussions in the multidisciplinary meeting of
inpatients and those receiving intravenous antibiotic therapy
(continued on next page)6. Quality management at the international level
“More radically, I would suggest that we don't need
international comparisons. Rather, what we need is inter-
national learning.” K. Walshe (2003) [83].
Table 4 (continued)
Area Proposed indicator
Shared care Number of patients followed in the satellite CF unit
Presence of input in the satellite CF unit from: dietitian,
physiotherapist and nurse, each with a special interest in CF
Presence of CF-dedicated clinics in the CF satellite unit
Periodic contact (once/twice a year) between CF care and
satellite CF unit annual assessment performed by
the CF Centre
Transitional
care
Availability of a system to allow transition from
paediatric to adult care
Presence of continuity of diagnostic and treatment protocols
Agreement between transition Centres on infection
control policies
Review of children and parents before the handover of care
Introduction to the new Centre before transition takes place
Presentation of differences between the transition Centres
performed before transition
Written report on the patient by all disciplines attached
to paediatric care
Welcome of the patient on first day of transition to
the new Centre
Annual
assessment
History of all medical and life events since the previous
annual review
Full clinical examination
Review by a CF specialist physiotherapist
Spirometry in patients over 5 years of age
Nutritional review by a CF specialist dietitian
Time with social worker and/or psychologist if required
Blood tests, sampling for faecal pancreatic elastase, faecal fat,
chest X-ray, liver ultrasound, sputum or swab as indicated in
the ‘Standards of care’ paper
Oral glucose tolerance test as indicated in the ‘Standards of
care’ paper]
Surveillance of bone mineral density
Repetition of sweat test for patients new to the Centre
Identification of genotype, if not already done, for patients new
to the Centre
Confirmation of pancreatic insufficiency for patients new to
the Centre
Introduction of the Centre to patients new to the Centre
Lung function
tests
Spirometry at every visit (FVC, FEV1, FEFmax, FEF25–75)
Pulmonary function tests other than spirometry when clinically
indicated
Execution of tests in a large ventilated room, using methods to
reduce cross infection
Segregation of patients according to their microbial status
New
diagnoses
Ability to visit the patient within 24 h from diagnosis
Implementation of initial assessment specifications
Initiation of educational programme
Initiation of treatment programme
Diagnosis in adulthood
Availability of tests indicated in the ‘Standards of care’ paper
ABPA, allergic bronchopulmonary aspergillosis; CF, cystic fibrosis; CT,
computed tomography; FEF, forced expiratory flow; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity.
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Comparisons of quality management practices across
countries pose the same problems as comparisons within the
same country, but add the complexity of differences in
healthcare systems and data collection practices. Dreachslin
et al. [84] identified the main obstacles to international dataquality comparisons as a lack of a uniform clinical database,
common definitions and data collection practices.
6.1.1. Choice of indicators and their definition
The choice of indicators is crucial when quality management
comparisons are carried out on patients' health status and on
healthcare systems. Various indicators have been suggested and
it is therefore important to consider the validity and necessity of
measures, as defined by Kerr [85,86]. Diagnosis, healthcare
services, and the outcomes of morbidity and mortality are
suggested indicators [84]. However, quality assessment and
improvement also require expert judgement and therefore
quality indicators are not the panacea; learning through the
sharing of experiences and networking is also important [87].
There is also a risk that a focus on indicators in certain areas
will exclude consideration of other equally important areas and
that long term outcomes may not be included [88].
The transferability of quality indicators for healthcare
systems across countries is feasible, but most often it is subject
to adaptation according to the specific context of the different
countries [86]. Particular attention should be paid to the level of
detail in the definition of international indicators of quality
management. In an attempt to have uniformity across countries
there is a risk that indicators will become uninformative and
result in the collection of information that is too generic [84].
Similarly, some indicators might reflect only local needs, and
are therefore unsuitable for international comparison [87].
Uniformity should be present for inclusion and exclusion
criteria: potential selection bias in patient registration and
information recording might affect the outcome of compari-
sons. It is therefore advisable to investigate whether inclusion/
exclusion criteria or different processes of registration might be
responsible for any differences found. To avoid the biases that
might be introduced by case-mix in outcome measures, the
recording of ‘near misses’ could be used instead [88].
Finally, data collection procedures and data quality should
be part of the quality management process. In fact, data quality
is an essential aspect of research, and one must remember the
old adage ‘garbage in, garbage out’. At the national level, the
reduction of missing data eased the comparison and improved
the follow-up in one study [31]. For this reason, data auditing
processes are advised [88].
6.1.2. PDSA cycles
It is well recognized that reporting of differences would be a
useless ranking exercise if not followed by a change in
behaviour/practices [88]. It is important to define a strategy for
identifying differences between countries, exploring why these
differences exist and building what Stern et al. called a learning
process and quality improvement procedure [31].
It is evident, though, that such a process is rather
complicated in international settings, where different factors
might lead to different outcomes and therefore confounding
effects might lead to different outcomes or different quality
indicators. Clearly, data analysis has a fundamental role:
comparisons can be carried out in a mere descriptive way by
means of summary tables and comparative graphs. However, a
Table 5
Proposed indicators for health outcomes and processes.
Area Indicator Stratification Limits
Outcome Median age By sex
Proportion of patients aged 18 years or more
Median FEV1% predicted By sex and age Patients aged 6+ years
Median BMI percentile By sex and age
Number of deaths in current year By sex
Median age at death (deaths in current year) By sex
Mean BMI By sex and age Patients aged 18+ years
Mean BMI percentile By sex and age Patients aged 2–17
Mean FEV1% predicted By sex and age Patients aged 6+ years
Mean, minimum, maximum, quartiles of age
Proportion of patients over 18 years
Proportion of patients deceased during current year
Mean and median age at death
Proportion of patients living with lung transplant
Proportion of patients living with liver transplant
Mean, minimum, maximum, quartiles of FEV1% predicted By age Patients without lung function
FEV1% predicted groups (b40/40–80/N80%) By age Patients without lung function
Prevalence of chronic infection by Pseudomonas aeruginosa
Prevalence of chronic infection by Burkholderia spp.
Prevalence of chronic infection by Staphylococcus aureus
Prevalence of infection by non-tuberculous mycobacteria
Prevalence of infection by Stenotrophomonas maltophilia
Mean, minimum, maximum, quartiles of Z-scores for height By age
Mean, minimum, maximum, quartiles of Z-scores for weight By age
Mean, minimum, maximum, quartiles of Z-scores for BMI By age
Proportion of patients with BMI b18.5 By age and sex Patients aged 18+ years
Prevalence of allergic bronchopulmonary aspergillosis
Prevalence of pneumothorax
Prevalence of haemoptysis
Prevalence of malignancy
Prevalence of liver disease
Number of patients living with transplanted lung(s) By age and sex
Number of patients living with transplanted liver By age and sex
Number of deaths in current year By age and sex
Age at death groups for deaths occurred in current year By sex
Cause of death for deaths occurred in current year
Processes Number of new diagnoses in current year
Percentage of new cases diagnosed by newborn screening in current year
Median age at diagnosis
Median age at diagnosis for new diagnoses
F508del genotype (homozygote/heterozygote/other/not genotyped)
Mean, minimum, maximum, quartiles of age at diagnosis
Age at diagnosis groups
Proportion of patients who underwent neonatal screening Patients aged 5+ years
Proportion of patients with DNA analysis
BMI, body mass index; FEV1, forced expiratory volume.
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should be carried out after also adjusting for potential
confounders. Moreover, after factors responsible for different
quality management levels have been identified, discussion on
the appropriateness of transferring practices across countries
are necessary, as what works in one country might not work in
another, or it might simply not be transferable [88].
Finally, some authors advocate the need for a governance
body that oversees the data quality improvement process
and sets up the appropriate measuring criteria, data col-
lection procedures, data analyses methods, and rewarding
schemes [88,89].6.2. International comparisons: a consensus
In order to set up an international quality improvement
process, agreement at the international level must be reached
on the following aspects: choice of indicators of quality
monitoring, choice of most suitable repository to store such
indicators, data analysis approaches (such as acknowledge-
ment of selection bias and confounding factors), implemen-
tation of PDSA cycles and governance of quality management
process. The following sections outline the consensus reached
for each of these aspects, and suggestions are made for areas
in need of work.
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Comparisons on the following areas of quality management
should be carried out internationally: healthcare services,
outcomes and data quality.
6.2.1.1. Healthcare services. Indicators for evaluation of
healthcare services have been proposed and used in the medical
literature, but in CF their use has not been well documented,
especially in international settings.
In the previous consensus statement on the standards of care
for CF, Kerem et al. [50] identified key services, facilities and
personnel to be adopted by specialized CF Centres, recom-
mended routines of CF care for outpatient, inpatient, shared and
transitional care, and recommended follow-up tests to be
carried out at annual assessment. These standards of care have
paved the way for the definition of indicators for international
comparison, in particular for the area of healthcare services.
Table 4 lists candidate indicators derived from the recommen-
dations updated in the present standards of care paper (see
Section 3, Quality management at the Centre level) [90].
ECFS encourages the creation of an international working
group, composed of experts in evaluation of healthcare
systems, CF specialists and data managers of CF databases,
with the aim of evaluating whether these candidate indicators
have the required characteristic for international comparisons.
In particular, evaluation of the proposed indicators should
concentrate on the following aspects:
• Do such indicators have the desired characteristics: validity,
necessity, transferability?
• Do such indicators have an adequate level of detail? Are
they informative or are they too vague? Do they reflect only
local needs?
• Is there a risk of tunnel vision with the choice of such
indicators?
• Are long-term indicators available and usable?
6.2.1.2. Health outcomes. In the CF literature, comparisons
of health outcomes have been carried out nationally
[30,31,52,91] and internationally [8,22,58,92–99]. Compar-
isons have been performed mainly for survival, lung function
and nutrition. Median age at death, median predicted survival,
FEV1, forced vital capacity, occurrence of lung infections,
weight, height and BMI have been used as indicators for
comparisons.
All these indicators have desirable characteristics: there is a
large consensus in the scientific CF community on their ability
to reflect the patient's health status; they are routinely recorded
in the clinical notes because they are used for the clinical
management of the patient; they have an adequate level of
detail to express the patient's health status; they do not reflect
only local needs; they focus on various aspects of CF; and some
of them take into account long-term outcomes. The main
problems with the use of such indicators have been in terms of
transferability: international comparisons through their use
have proven difficult due to different timings of measurements
(e.g. recording of best vs. last FEV1 of the year), dissimilardefinitions (e.g. chronicity of infections) [100], different
detection rates (e.g. genotyping) or frequency of sampling
(e.g. microbiological testing) [100,101], potential patient
selection bias [58,100,101], amount of missing data [100].
ECFS urges the international CF community to come to an
agreement on core aspects of CF health outcomes, and report
national-level indicators on such aspects on a routine basis,
primarily through national CF registries. A proposal on sharing
such information was put forward in 2009 [102] and a choice of
Centre-level indicators was outlined. This proposal has been
further developed and other indicators have been proposed
[103].
Another example of international comparison of health
outcomes and health processes (e.g. diagnostic practices) is
given in the annual data report of the European Cystic Fibrosis
Society Patient Registry [14,100]. Table 5 summarizes the
indicators on health outcomes and health processes that should
be considered and improved for international comparison
purposes [100,102].
6.2.1.3. Data quality. Data quality should be part of an
international quality monitoring process. Improvement of the
level of accuracy of information recorded should be attained
by motivation and proper training of the individuals in charge
of data retrieval and data recording, by implementation of
automatic systems for error detection, and by implementation
of efficient procedures for error correction. Initiatives for
sharing international learning and expertise on data quality
control processes should be encouraged, such as the one
initiated by the European Cystic Fibrosis Society Patient
Registry [13].
6.2.2. Data analysis and metadata sharing
Outcomes of international comparisons are particularly
prone to differences that might be due to confounding factors
and to differences in patient selection. These confounders
should be accounted for in the data analysis phase. Statistical
methods for confounding control and case-mix adjustment can
be used, although their implementation might be difficult in
such a complex context, but at least simpler methods such as
stratification and subgroup analysis should be used whenever
necessary. It is essential that potential sources of patient
selection bias are carefully scrutinized so that fair comparisons
are carried out across countries in groups of patients that are as
homogeneous as possible.
Another fundamental aspect of data analysis is the
disclosure of all important technical information that might
affect results. Reference values used to compute standard
deviation scores for anthropometric measurements, or
equations used to compute percentage of predicted values
for lung function tests, specification of inclusion/exclusion
criteria are examples of technical information that should be
specified.
6.2.3. Data collection and choice of repository
The previous sections have described the elements
needed for international comparisons: choice of indicators
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mentation of data analysis methods accounting for confound-
ing effect and selection bias, the sharing of knowledge on data
quality, the sharing of technical information on data analyses.
All these elements could be conveniently gathered in a unique
repository, such as the one proposed by Sims [104].
International agreement should be reached on the choice of
such a repository, and on the choice of the kind of information
to be stored, as well as the level of detail. Examples of
information stored are: aggregated results of indicators chosen
for international comparisons, documentation of methodology
used for data collection and data analysis, material useful for
the exchange of experiences with different initiatives for
quality improvement.
6.2.4. Implementation of PDSA cycles and governance of
quality management processes
For the quality monitoring process to be effective, the
PDSA cycle should be appropriately implemented and an
efficient governance system should be set up.
It is recommended that international agreement is reached
on how the governance process should be organized and
sustained. A defined group of dedicated people, with the
ability to introduce changes and measure the impact of those
changes, should be set up. If the indicators chosen for
international comparisons are not present in the existing
databases (e.g. patient registries, administrative databases,
routine health statistics reports), national registries should be
urged to collect such information and to create a specific
repository to store aggregated information.
Stimulation of participation in quality monitoring
programmes, promotion of networking and experience sharing
for the learning process, and audit on indicators and on data
collection procedures are among the tasks of this group.
6.2.5. Patient involvement in international comparisons
Patient involvement at each level of the quality monitoring
process is fundamental: quality improvement is for the patients'
benefit and their empowerment and contribution to the process
are essential.
Active involvement of patients is successfully attained in
many countries through the sharing of information in which
technical jargon is avoided. The distribution of fact leaflets,
patient-friendly versions of annual data reports, and web
pages of CF registries dedicated to the patients are examples
of how the CF and registry specialists have granted the
patients access to information in a transparent and compre-
hensible way. Patients thus have the opportunity to be an
active part of healthcare, and through their representatives in
the governance bodies can influence the implementation of
the changes necessary to improve quality.
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